Investors



Stock price graph

Horizon Pharma, Inc. is a specialty pharmaceutical company that has developed and is commercializing products to primary care, orthopedic surgeons and rheumatologists. The Company markets DUEXIS®, RAYOS®/LODOTRA® and VIMOVO® , which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company's strategy is to develop, acquire or in-license additional innovative medicines where it can execute a targeted commercial approach among specific target physicians while taking advantage of its commercial strengths and the infrastructure the Company has put in place. 

 

Contacts:

Investors

Bob De Vaere
Chief Financial Officer
Horizon Pharma, Inc.
520 Lake Cook Road, Suite 520
Deerfield, IL 60015
bd@horizonpharma.com

Media

BiotechComm
E. Blair Clark-Schoeb
(917) 432-9275
blair@biotechcomm.com

View all   RSSRecent Releases

Horizon Pharma to Host Conference Call and Webcast to Discuss Second Quarter 2014 Financial Results on August 7, 2014

DEERFIELD, IL -- (Marketwired) -- 07/29/14 -- Horizon Pharma, Inc. (NASDAQ: HZNP) announced today that its second quarter 2014 financial results will be released on Thursday, August 7, 2014. Following the announcement, Horizon's management will host a live conference call and webcast at 8:00 am Eastern Time to review the Company's financial and operating results and provide a general business update. The live webcast and a replay may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. Please connect to the Company's website at least 15 minutes prior to t...

Read more »

Horizon Pharma Announces Execution of $300 Million Senior Secured Credit Agreement in Connection With the Proposed Acquisition of Vidara

DEERFIELD, IL -- (Marketwired) -- 06/19/14 -- Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that it has entered into an agreement with a group of lenders to provide Horizon with $300 million in financing through a five year senior secured credit facility. Funding is expected to occur coincident with the closing of the proposed acquisition of Vidara Therapeutics International Ltd. This agreement replaces the $250 million bridge loan commitment received from Deerfield Management Company, L.P., which the Company announced on March 19, 2014. The Company intends to use proceeds...

Read more »

Horizon Pharma Announces Robert J. De Vaere to Retire and Names Paul W. Hoelscher Chief Financial Officer

DEERFIELD, IL -- (Marketwired) -- 06/18/14 -- Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Robert J. De Vaere, its current Chief Financial Officer, will retire on September 30, 2014. The Company has also named Paul W. Hoelscher as Executive Vice President, Finance, effective June 23, 2014 and its Chief Financial Officer, effective October 1, 2014. At the time of his retirement, Mr. De Vaere will enter into a one-year consulting agreement with the Company to support the ongoing integration of Vidara following the closing of the acquisition and to provide general business support...

Read more »

Horizon Pharma to Present at the JMP Securities Healthcare Conference 2014

DEERFIELD, IL -- (Marketwired) -- 06/17/14 -- Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Todd N. Smith, executive vice president, chief commercial officer, will present in a fireside chat format discussion at the JMP Securities Healthcare Conference 2014 on Tuesday, June 24, 2014 at 11:30 a.m. Eastern Time in New York, NY. Mr. Smith will provide an overview of the Company and its corporate activities. The presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. A replay of the webcast will be available for...

Read more »

Horizon Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

DEERFIELD, IL -- (Marketwired) -- 06/06/14 -- Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that on June 6, 2014 the Compensation Committee of its Board of Directors granted inducement awards to five new employees. Effective on June 6, 2014, the Compensation Committee granted: (1) stock options to five new non-executive employees to purchase up to 143,800 shares of Horizon's common stock, with a per share exercise price equal to $14.48, the fair market value on the grant date, that will vest over four years, with 25% of the underlying shares vesting after one year and an ad...

Read more »


View all »Events & Presentations

Aug 7, 2014 at 8:00 AM ET
Horizon Pharma Second Quarter 2014 Earnings Call